Transcriptional signaling pathways inversely regulated in Alzheimer's disease and glioblastoma multiform

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Liu, Timothy ^a   Ren, Ding ^a,c   Zhu, Xiaoping ^a   Yin, Zheng ^a,b   Jin, Guangxu ^a,b   Zhao, Zhen ^a,b   Robinson, Daniel ^a   Li, Xuping ^a,b   Wong, Kelvin ^a,b   Cui, Kemi ^a   Zhao, Hong ^a,b   Wong, Stephen T C ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c No 85 Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PROTEIN KINASE B;

ALZHEIMER DISEASE; ANIMAL; ASTROCYTE; BIOLOGICAL MODEL; CASE CONTROL STUDY; CELL LINE; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE MODEL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; CASE-CONTROL STUDIES; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84890190202     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03467     Document Type: Article

References (53)

1. Ou, S.-M., Lee, Y.-J., H, Y.-W., Liu, C.-J., Chen, T.-J., Fuh, J.-L. & Wang, S.-J. Does Alzheimer's Disease Protect against Cancers? A Nationwide Population-Based Study. Neuroepidemiology 40, 42-49 (2013).
2. Driver, J. A. et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ 344, e1442 (2012).
3. Roe, C. M., Behrens, M. I., Xiong, C.,Miller, J. P. &Morris, J. C. Alzheimer disease and cancer. Neurology 64, 895-898 (2005). (Pubitemid 40316334)
4. Roe, C. M. et al. Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74, 106-112 (2010).
5. Musicco, M. et al. Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. Neurology 81, 322-328 (2013).
6. Driver, J. A., Kurth, T., Buring, J. E., Gaziano, J. M. & Logroscino, G. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease. Cancer Causes Control 18, 705-711 (2007). (Pubitemid 46988238)
7. Driver, J. A., Logroscino, G., Buring, J. E., Gaziano, J. M.& Kurth, T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 16, 1260-1265 (2007). (Pubitemid 46984968)
8. Behrens, M. I., Lendon, C. & Roe, C. M. A common biological mechanism in cancer and Alzheimer's disease? Curr Alzheimer Res 6, 196-204 (2009).
9. Driver, J. A. & Lu, K. P. Pin1: a new genetic link between Alzheimer's disease, cancer and aging. Curr Aging Sci 3, 158-165 (2010).
10. Blalock, E. M. et al. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101, 2173-2178 (2004). (Pubitemid 38229034)
11. Wulf, G. M. et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20, 3459-3472 (2001). (Pubitemid 32634353)
12. Pastorino, L. et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440, 528-534 (2006).
13. Manoukian, A. S. & Woodgett, J. R. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 84, 203-229 (2002). (Pubitemid 34188198)
14. Fuentealba, R. A. et al. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Res Brain Res Rev 47, 275-289 (2004). (Pubitemid 39574325)
15. Wulf, G., Garg, P., Liou, Y. C., Iglehart, D. & Lu, K. P. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J 23, 3397-3407 (2004). (Pubitemid 39209163)
16. Lim, J. et al. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest 118, 1877-1889 (2008). (Pubitemid 351632390)
17. Noble, W. et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565 (2003). (Pubitemid 36645031)
18. Wang, J. Z., Wu, Q., Smith, A., Grundke-Iqbal, I. & Iqbal, K. Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by Akinase. FEBS Lett 436, 28-34 (1998). (Pubitemid 28454601)
19. Paris, D. et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis 7, 75-85 (2004).
20. Xie, R. L. et al. The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. J Biol Chem 278, 26589-26596 (2003).
21. Bordin, S. & Tan, X. C1q arrests the cell cycle progression of fibroblasts in G(1) phase: role of the cAMP/PKA-I pathway. Cell Signal 13, 119-123 (2001). (Pubitemid 32222981)
22. Lama, G. et al. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. Int J Oncol 30, 1333-1342 (2007).
23. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002). (Pubitemid 34790756)
24. Mrak, R. E. & Griffin, W. S. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 22, 903-908 (2001). (Pubitemid 34066557)
25. Grolla, A. A. et al. Abeta leads to Ca(21) signaling alterations and transcriptional changes in glial cells. Neurobiol Aging 34, 511-522 (2013).
26. Capiod, T. S. Y., Skryma, R. & Prevarskaya, N. in Subcell Biochem, Vol. 45, 405-427 (2007).
27. Zhao, H. et al. Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid beta protein. Cancer Cell Int 9, 15 (2009).
28. Walsh, D. M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002). (Pubitemid 34288854)
29. Tamagno, E. et al. JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol Aging 30, 1563-1573 (2009).
30. Scholl, F. A. et al. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Dev Cell 12, 615-629 (2007). (Pubitemid 46523646)
31. Holland, E. C. et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25, 55-57 (2000). (Pubitemid 30257036)
32. Hsiao, K. et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996). (Pubitemid 26332733)
33. Sunayama, J. et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 28, 1930-1939 (2010).
34. Vagnucci, A. H., Jr. &Li, W. W. Alzheimer's disease and angiogenesis. Lancet 361, 605-608 (2003). (Pubitemid 36207483)
35. Das, S. & Marsden, P. A. Angiogenesis in glioblastoma. N Engl J Med 369, 1561-1563 (2013).
36. Finkel, T., Serrano, M. & Blasco, M. A. The common biology of cancer and ageing. Nature 448, 767-774 (2007). (Pubitemid 47266334)
37. Park, L. et al. Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc Natl Acad Sci U S A 110, 3089-3094 (2013).
38. Thomas, S. N. et al. Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach. Acta Neuropathol 123, 105-117 (2012).
39. Herrup, K. & Yang, Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci 8, 368-378 (2007). (Pubitemid 46652467)
40. Ye, W. & Blain, S. W. S phase entry causes homocysteine-induced death while ataxia telangiectasia and Rad3 related protein functions anti-apoptotically to protect neurons. Brain 133, 2295-2312 (2010).
41. Arendt, T., Bruckner, M. K., Mosch, B. & Losche, A. Selective cell death of hyperploid neurons in Alzheimer's disease. Am J Pathol 177, 15-20 (2010).
42. Bester, A. C. et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 145, 435-446 (2011).
43. Ng, S. S. et al. Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma. J Natl Cancer Inst 99, 936-948 (2007). (Pubitemid 47073500)
44. Dai, R., Chen, R. & Li, H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J Oncol 34, 1749-1757 (2009).
45. Rommel, C. et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286, 1738-1741 (1999). (Pubitemid 129515881)
46. Liu, J. F. et al. Functional Rac-1 and Nck signaling networks are required for FGF- 2-induced DNA synthesis in MCF-7 cells. Oncogene 18, 6425-6433 (1999).
47. Kim, S. K. et al. ERK1/2 is an endogenous negative regulator of the gammasecretase activity. FASEB J 20, 157-159 (2006).
48. Mei, M. et al. Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease. J Neurochem 99, 1377-1388 (2006). (Pubitemid 44730092)
49. Spitzer, P. et al. Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. Int J Alzheimers Dis 2011, 739847 (2011).
50. Zhao, H. et al. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Res Treat 131, 425-436 (2012).
51. Wang, L. et al. Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion. J Neurosci Res 91, 128-137 (2013).
52. Andersen, J. N. et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Science translational medicine 2, 43ra55.
53. Jin, G. et al. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res 72, 33-44 (2012).